Navigation Links
Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment

A new drug called febuxostat has been found to reduce plasma levels of uric acid more effectively in Gout than the currently used drug allopurinol. If the results of the clinical trial are successful//, then it would mean the end of a 40 year search for successful treatment of Gout.

Gout is characterized by accumulation and deposition of needle shaped uric acid crystals in the joints, thereby leading to inflammation and pain. Progressively, it leads to a condition called ‘Gouty arthritis’ and is associated by a significant reduction in joint mobility.

The only existing standard treatment for Gout is administration of allopurinol, which reduces the levels of uric acid production by blocking certain key steps in uric acid synthesis. In addition, it also decreases the plasma levels of uric acid over a period of time.

The study was conducted amongst a group of 762 patients, diagnosed to suffer from Gout and is believed to be the largest clinical trial ever done on patients with Gout. The mechanism of action of Febuxostat is very similar to allopurinol.

The study participants were either given allopurinol or febuxostat (two different doses) as a form of treatment, the goal of which was to reduce plasma uric acid levels by as much as 6 mg/dl. Allopurinol treatment was taken by 21% of the members, followed by 53 and 62% who took 80 and 120mg of febuxostat respectively.

At the end of the study, it was found that the new drug was more effective than allopurinol when used for more than a year, as revealed by statistical tests. However, a large number of patients were found to discontinue from the study due to the high incidence of adverse effects. The main site of drug metabolism is the liver which facilitates administration of the drug to patients with compromised kidney function as well.

The drug has not yet been approved by the U.S. Food and Drug Administration agency (FDA) for therapeutic use. More studies are clearly indicated to determine the long term clinical benefits of the new drug, taking into critical consideration the safety.
'"/>




Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Renal Trails Do Not Have Sufficient Women Participants
7. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Cancer Clinical Research in India
10. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
11. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Lice Troopers, ... lice cases in families with school-aged children since the holiday season. , “It ... holidays with their families, sharing hugs and taking photos, which is the head-to-head gateway ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology: